Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

FGF21 Levels in Pheochromocytoma/Functional Paraganglioma

J. Klímová, T. Zelinka, J. Rosa, B. Štrauch, D. Haluzíková, M. Haluzík, R. Holaj, Z. Krátká, J. Kvasnička, V. Ďurovcová, M. Matoulek, K. Novák, D. Michalský, J. Widimský, O. Petrák,

. 2019 ; 11 (4) : . [pub] 20190405

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19029199

Grantová podpora
AZV 16-30345A Ministerstvo Zdravotnictví Ceské Republiky
NV16-30345A MZ0 CEP - Centrální evidence projektů

Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients and 26 lean healthy controls. 27 patients with PPGL were examined one year after tumor removal. Basic anthropometric and biochemical measurements were done. Energy metabolism was measured by indirect calorimetry (Vmax-Encore 29N). FGF21 was measured by ELISA. FGF21 was higher in PPGL than in controls (174.2 (283) pg/mL vs. 107.9 (116) pg/mL; p < 0.001) and comparable with obese (174.2 (283) pg/mL vs. 160.4 (180); p = NS). After tumor removal, FGF21 decreased (176.4 (284) pg/mL vs. 131.3 (225) pg/mL; p < 0.001). Higher levels of FGF21 were expressed, particularly in patients with diabetes. FGF21 positively correlated in PPGL with age (p = 0.005), BMI (p = 0.028), glycemia (p = 0.002), and glycated hemoglobin (p = 0.014). In conclusion, long-term catecholamine overproduction in PPGL leads to the elevation in serum FGF21, especially in patients with secondary diabetes. FGF21 levels were comparable between obese and PPGL patients, despite different anthropometric indices. We did not find a relationship between FGF21 and hypermetabolism in PPGL. Tumor removal led to the normalization of FGF21 and the other metabolic abnormalities.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19029199
003      
CZ-PrNML
005      
20190819085026.0
007      
ta
008      
190813s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers11040485 $2 doi
035    __
$a (PubMed)30959789
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Klímová, Judita $u Third Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic. Judita.Klimova@vfn.cz.
245    10
$a FGF21 Levels in Pheochromocytoma/Functional Paraganglioma / $c J. Klímová, T. Zelinka, J. Rosa, B. Štrauch, D. Haluzíková, M. Haluzík, R. Holaj, Z. Krátká, J. Kvasnička, V. Ďurovcová, M. Matoulek, K. Novák, D. Michalský, J. Widimský, O. Petrák,
520    9_
$a Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients and 26 lean healthy controls. 27 patients with PPGL were examined one year after tumor removal. Basic anthropometric and biochemical measurements were done. Energy metabolism was measured by indirect calorimetry (Vmax-Encore 29N). FGF21 was measured by ELISA. FGF21 was higher in PPGL than in controls (174.2 (283) pg/mL vs. 107.9 (116) pg/mL; p < 0.001) and comparable with obese (174.2 (283) pg/mL vs. 160.4 (180); p = NS). After tumor removal, FGF21 decreased (176.4 (284) pg/mL vs. 131.3 (225) pg/mL; p < 0.001). Higher levels of FGF21 were expressed, particularly in patients with diabetes. FGF21 positively correlated in PPGL with age (p = 0.005), BMI (p = 0.028), glycemia (p = 0.002), and glycated hemoglobin (p = 0.014). In conclusion, long-term catecholamine overproduction in PPGL leads to the elevation in serum FGF21, especially in patients with secondary diabetes. FGF21 levels were comparable between obese and PPGL patients, despite different anthropometric indices. We did not find a relationship between FGF21 and hypermetabolism in PPGL. Tumor removal led to the normalization of FGF21 and the other metabolic abnormalities.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zelinka, Tomáš $u Third Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic. Tomas.Zelinka@vfn.cz.
700    1_
$a Rosa, Ján $u Third Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic. Jan.Rosa@vfn.cz.
700    1_
$a Štrauch, Branislav $u Third Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic. Branislav.Strauch@vfn.cz.
700    1_
$a Haluzíková, Denisa $u Institute of Sports Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, 120 00 Prague, Czech Republic. Denisa.Haluzikova@vfn.cz.
700    1_
$a Haluzík, Martin $u Centre for Experimental Medicine and Diabetes Centre, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic. martin.haluzik@ikem.cz. Institute for Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital in Prague, 128 08 Prague, Czech Republic. martin.haluzik@ikem.cz.
700    1_
$a Holaj, Robert $u Third Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic. Robert.Holaj@vfn.cz.
700    1_
$a Krátká, Zuzana $u Third Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic. Zuzana.Kratka@vfn.cz.
700    1_
$a Kvasnička, Jan $u Third Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic. Jan.Kvasnicka3@vfn.cz.
700    1_
$a Ďurovcová, Viktorie $u Third Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic. viktoria.durovcova@gmail.com.
700    1_
$a Matoulek, Martin $u Third Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic. martin.matoulek@vstj.cz.
700    1_
$a Novák, Květoslav $u Department of Urology of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic. Kvetoslav.Novak@vfn.cz.
700    1_
$a Michalský, David $u First Department of Surgery of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic. david.michalsky@vfn.cz.
700    1_
$a Widimský, Jiří $u Third Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic. Jiri.Widimsky@vfn.cz.
700    1_
$a Petrák, Ondřej $u Third Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic. Ondrej.Petrak@vfn.cz.
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 11, č. 4 (2019)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30959789 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190819085300 $b ABA008
999    __
$a ind $b bmc $g 1434348 $s 1067659
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 11 $c 4 $e 20190405 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a AZV 16-30345A $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a NV16-30345A $p MZ0
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace